Lone Star Fund XII, L.P., a fund managed by Lone Star Americas Acquisitions, Inc. entered into an agreement to acquire 60% stake in Capsules & Health Ingredients business of Lonza Group AG from Lonza Group AG for CHF 1.7 billion.
Published on 03/07/2026
at 12:51 am IST - Modified on 03/06/2026
Lone Star Fund XII, L.P., a fund managed by Lone Star Americas Acquisitions, Inc. entered into an agreement to acquire 60% stake in Capsules & Health Ingredients (CHI) business of Lonza Group AG from Lonza Group AG (SWX:LONN) for CHF 1.7 billion on March 6, 2026. A cash consideration of CHF 1.7 billion will be paid by Lone Star Americas Acquisitions, Inc. The transaction is for an enterprise value of CHF 2.3 billion at closing. Lonza will retain a 40% stake in Capsules & Health Ingredients, with an additional preferential participation in a future exit. Considering the leading position and strengths of the CHI business after its return to growth in 2025, the total undiscounted value of the proceeds for Lonza from the full exit from CHI, including upfront proceeds, proceeds from future sale of its retained 40% stake and preferential participation in exit proceeds, is expected to be at or above CHF 3 billion. CHF 500 million will be returned to shareholders through a share buyback following receipt of proceeds. As part of its wider portfolio transformation, Lonza has also signed agreements to divest the Personalized Medicines business, the MODA software platform, and the small molecules micronization site in Monteggio.
The transaction is subject to customary closing conditions relating to regulatory approvals and completion of the legal separation of CHI from Lonza?s wider business. The transaction is expected to close in H2 2026. BofA Securities and Centerview Partners acted as joint financial advisors to Lonza. Lonza plans to invest the upfront proceeds into additional organic growth opportunities in line with the One Lonza Strategy, as well as bolt-on acquisitions. Tino Gaberthüel, Simone Ehrsam, Peter Ling and Franziska Stadtherr-Glättli of Lenz & Staehelin acted as legal advisor for Lone Star Americas Acquisitions, Inc. Andreas Hinsen and Anna Capaul acted as legal advisor for Lonza Group AG. Marco G. Carbonare, Rupert Cheyne, Martina Farkas, Simon Branigan, Michael Leicht, Jamie Coomber, Matthew Devey, Ruprecht Freiherr von Maltzahn, Greg Palmer, Heiko Schiwek, Christoph Barth, Jana Hager, Paul Joseph, Wendy Suh, Atif Wolfgang Bhatti, Jack Harrison and Nursel Tevetoglu of Linklaters LLP acted as legal advisor for Lonza Group AG. Jacob Traff, James Hunn, David Higgins, Jamie Gordon, Daniel Borg, Sam Sherwood, Alexander Bond, André Duminy, Corina Demeter-Olive, Ceinwen Rees, Joseph Tootle, Michael Akpomiemie and Tim Volkheimer of Kirkland & Ellis acted as legal advisor for Lone Star Americas Acquisitions, Inc. Christian Kames of Lazard & Co. GmbH acted as financial advisor to Lone Star Americas Acquisitions, Inc.
Lonza Group AG is one of the world leaders of the contract development and manufacturing of pharmaceutical and biotechnology products. Net sales break down by family of products and services as follows:
- biologics and bio-pharmaceuticals (55.9%): microbiological fermentation products, mammalian cell-based bio-pharmaceuticals, monoclonal antibodies, therapeutic proteins, etc.;
- synthesis products (24.7%): chemopharmaceutical products, bioconjugates, small molecules, active pharmaceutical ingredients, complex intermediates, etc.;
- specialised therapeutic products (15.8%): cell and gene therapies, synthetic therapeutic nucleic acids, oligonucleotides, microbial biological products, etc.;
- others (3.6%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Lone Star Fund XII, L.P., a fund managed by Lone Star Americas Acquisitions, Inc. entered into an agreement to acquire 60% stake in Capsules & Health Ingredients business of Lonza Group AG from Lonza Group AG for CHF 1.7 billion.